Intracerebral hemorrhage is the sudden burst of blood into the brain tissue itself.
It causes sudden onset of focal neurological deficit.
The focal neurologic findings are related to the anatomic location, size and speed of development of intracerebral hemorrhage.
Neurological deficit usually progresses over a minute to an hour.
Rapid recognition and diagnosis of intracerebral hemorrhage are essential because of its frequently rapid progression.

Surgical Intervention

  • The usefulness of surgical therapy, in most patients with intracerebral hemorrhage (ICH), remains controversial
    • Surgery may limit mechanical compression and neurotoxic effects of blood but surgical risks in a bleeding patient may be greater
  • Minimally invasive procedures including stereotactic- or endoscopic-guided evacuation with or without thrombolysis is considered investigational
  • Very early craniotomy may increase the risk of recurrent bleeding
  • For patients with hydrocephalus with decreased level of consciousness, ventricular drainage may be a reasonable option
  • Ventricular drainage alone rather than surgical evacuation is not recommended

Surgical Candidates

  • Cerebellar hemorrhage >3 cm with the following:
    • Neurological deterioration or
    • Brain stem compression and/or hydrocephalus from ventricular obstruction
  • Lobar clots >30 mL & within 1 cm of the surface
  • Intracerebral hemorrhage with mass effect lesion if surgically accessible and patient has chance of good outcome
  • Young patients with moderate-large lobar hemorrhage and who are deteriorating clinically
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Editor's Recommendations
Most Read Articles
10 Mar 2018
Compared to triple therapy, dual antithrombotic therapy yields reduced bleeding without excess ischaemic and thromboembolic cardiac events in patients with long-term indication to chronic oral anticoagulation following percutaneous coronary intervention, according to a new study.
Roshini Claire Anthony, 4 days ago

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Pearl Toh, 3 days ago
Pearl Toh spoke with Dr Andrew Kates, vice chair of ACC.18 Scientific Session about what’s new in cardiology and what ACC.18 has to offer.
4 days ago
Slideshow: Highlights from the American College of Cardiology 67th Annual Scientific Session (ACC)